Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: Prediction and treatment with cyclosporine

Journal of Rheumatology

Volumn 26, Issue 7, 1999, Pages 1527-1533

  Nawata, Yasushi ^b   Kurasawa, Kazuhiro ^b   Takabayashi, Katuhiko ^b   Miike, Satoshi ^b   Watanabe, Norihiko ^b   Hiraguri, Masaki ^b   Kita, Yasuhiko ^b   Kawai, Mitsuru ^b   Saito, Yasushi ^b   Iwamoto, Itsuo ^a  

^a CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

CPK; Cyclosporine; Dermatomyositis; Interstitial pneumonitis; Polymyositis

Indexed keywords

CYCLOSPORIN;

ADULT; ARTICLE; CORTICOSTEROID BLOOD LEVEL; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ADULT; AUTOIMMUNE DISEASES; CYCLOSPORINE; DERMATOMYOSITIS; DRUG RESISTANCE; FEMALE; GLUCOCORTICOIDS; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; POLYMYOSITIS; PREDNISOLONE; SURVIVAL RATE;

EID: 0033051219     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-7.
2. Plotz PH, Rider LG, Targoff IN, Raben N, O'Hanlon TP, Miller FW. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 1995;122:715-24.
3. Frazier AR, Miller RD. Interstitial pneumonitis is associated with polymyositis and dermatomyositis. Chest 1974;65:403-7.
4. Salmeron G, Greenberg SD, Lidsky MD. Polymyositis and diffuse interstitial lung disease. Arch Intern Med 1981;141:1005-10.
5. Songcharoen S, Raju SF, Pennebaker JB. Interstitial lung disease in polymyositis and dermatomyositis. J Rheumatol 1980;7:353-60.
6. Dickey BF, Myers AR. Pulmonary disease in polymyositis/dermatomyositis. Semin Arthritis Rheum 1984;14:60-76.
7. Lakhanpal S, Lie JT, Conn DL, Martin WJ. Pulmonary disease in polymyositis/dermatomyositis: a clinicopathological analysis of 65 autopsy cases. Ann Rheum Dis 1987;46:23-9.
8. Takizawa H, Shiga J, Moroi Y, Miyachi S, Nishiwaki M, Miyamoto T. Interstitial lung disease in dermatomyositis: clinicopathological study. J Rheumatol 1987;14:102-7.
9. Arsura EL, Greenberg AS. Adverse impact of interstitial pulmonary fibrosis on progress in polymyositis and dermatomyositis. Semin Arthritis Rheum 1988;18:29-37.
10. Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV. Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 1990;141:727-33.
11. Crystal RG, Gadek JE, Ferrans VJ, Fulmer JD, Line BR, Hunninghake GW. Interstitial lung disease: current concepts of pathogenesis, staging and therapy. Am J Med 1981;70:543-68.
12. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992;326:1654-60.
13. Yoshida S, Akizuki M, Mimori T, Yamagata H, Inada S, Homma M. The precipitating antibody to acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum 1983;26:604-11.
14. Fernandes L, Goodwill CJ. Dermatomyositis without apparent myositis complicated by fibrosing alveolitis. J Roy Soc Med 1979;72:777-9.
15. Fergusson RJ, Davidson NM, Nuki G, Crompton GK. Dermatomyositis and rapidly progressive fibrosing alveolitis. Thorax 1983;38:71-2.
16. Fudman EJ, Schnitzer TJ. Dermatomyositis without creatine kinase elevation. A poor prognostic sign. Am J Med 1986;80:329-32.
17. Cosnes A, Amaudric F, Gherardi R, et al. Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol 1995;131:1381-5.
18. Stonecipher MR, Jorizzo JL, White WL, Walker FO, Prichard E. Cutaneous changes of dermatomyositis in patients with normal muscle enzymes: dermatomyositis sine myositis? J Am Acad Dermatol 1993;28:951-6.
19. DeVere R, Bradley WG. Polymyositis: its presentation, morbidity and mortality. Brain 1975;98:637-66.
20. Leff RL, Love LA, Miller FW, et al. Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. Lancet 1992;339:1192-5.
21. Hashimoto Y, Nawata Y, Kurasawa K, et al. Investigation of EB virus and cytomegalovirus in rapidly progressive interstitial pneumonitis in polymyositis/dermatomyositis by in situ hybridization and polymerase chain reaction. Clin Immunol Immunopathol 1995;77:298-306.
22. Tokuda M, Kurata N, Mizoguchi A, et al. Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum 1994;37:551-8.
23. Dijkmans BSC, van Rijthoven AWAM, Goei The HS, Boers M, Cats A. Cyclosporin in rheumatoid arthritis. Semin Arthritis Rheum 1992;22:30-6.
24. Pasero G, Priolo F, Marubini E, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996;39:1006-15.
25. Alegre J, Teran J, Alvarez B, Viejo JL. Successful use of cyclosporine for the treatment of aggressive pulmonary fibrosis in a patient with rheumatoid arthritis. Arthritis Rheum 1990;33:1594-6.
26. Puttick MP, Klinkhoff AV, Chalmers A, Ostrow DN. Treatment of progressive rheumatoid interstitial lung disease with cyclosporine. J Rheumatol 1995;22:2163-5.
27. Rebuck AS, Stiller CR, Braude AC, Laupacis A, Cohen RD, Chapman KR. Cyclosporine for pulmonary sarcoidosis. Lancet 1984;1:1174.
28. Moolman JA, Bardin PG, Rossouw DJ, Joubert JR. Cyclosporine as a treatment for interstitial lung disease of unknown aetiology. Thorax 1991;46:592-5.
29. Bendzen K, Tvede N, Andersen V, Bendixen G. Cyclosporine for polymyositis. Lancet 1984;1:792-3.
30. Heckmatt J, Nasson N, Saunders C, et al. Cyclosporin in juvenile dermatomyositis. Lancet 1989;1:1063-6.
31. Lueck CJ, Trend P, Swash M. Cyclosporin in the management of polymyositis and dermatomyositis. J Neurol Neurosurg Psy 1991;54:1007-8.
32. Gruhn WB, Diaz-Buxo JA. Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis/polymyositis. J Rheumatol 1987;14:1045-7.
33. Maeda K, Kimura R, Komuta K, Igarashi T. Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand J Rheumatol 1997;26:24-9.
34. Bierer BE, Hollander G, Fruman D, Burakoff SJ. Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol 1993;5:763-73.
35. Jonat C, Rahmsdorf HJ, Park KK, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 1990;62:1189-204.
36. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995;270:286-90.
37. Brinkmann V, Kristofic C. Regulation by corticosteroids of Th1 and Th2 cytokine production in human CD4+ effector T cells generated from CD45RO- and CD45RO+ subsets. J Immunol 1995;155:3322-8.